Researchers are developing a new generation of drugs that could have the pain-relieving power of opioids minus the dangerous side effects such as respiratory depression. Three compounds with potential are oliceridine, mitragynine pseudoindoxyl and PZM21, which bind to opioid receptors but activate different signaling pathways than current opioid drugs.
Researchers are studying whether naked mole rats, which do not seem to feel certain types of pain, hold clues to developing new treatments for humans. A study in the journal Cell Reports is focused on thermal hyperalgesia, which the naked mole rats apparently do not experience at levels found in other animals.
NEW Pain Management Education Series – Save 10% Essentials of Pain Management reviews the fundamentals of pain medicine including treatment of common pain disorders in clinical situations. This series will advance patient outcomes by providing continuing education to assess, treat and manage various pain disorders. Save 10%! Code: APS10. Learn more.
Migraine relief from spinal manipulation therapy may be linked to a placebo effect, researchers reported in the European Journal of Neurology. The study found similar reductions in migraine days among patients in a spinal manipulation intervention group and a sham spinal manipulation group, and the benefits lasted longer than those for a group that received standard pharmacologic treatment.
A lower dosage strength for Orexo's opioid dependence treatment Zubsolv, or buprenorphine/naloxone sublingual tablet, has been approved by the FDA. The drug will now be available in six strengths, including the new 0.7mg/0.18mg sublingual tablet.
CDC data show 14.6 million Americans reported severe joint pain in 2014, up from about 10.5 million in 2002. The study in the CDC's Morbidity and Mortality Weekly Report found severe joint pain was cited by 46% of adults with disabilities and 52% of those who said they were unable to work.
The Drug Enforcement Administration has ordered drugmakers to decrease production of prescription opioid medications by at least 25% next year, and production of some, including hydrocodone, must be cut by 34%. The decision follows recommendations from the CDC that health care professionals reduce prescribing of the drugs.
The APS Scientific Program Committee (SPC) invites you to submit a poster abstract and present to hundreds of pain professionals at the 2017 Annual Scientific Meeting in Pittsburgh. The SPC is seeking original research that has not been previously presented or published elsewhere, prior to the APS meeting. All accepted posters will be presented at the 2017 Annual Scientific Meeting, May 17-20, 2017, and will be published in a supplement to The Journal of Pain. Submissions are due Tuesday, Nov. 15. Learn more.
The APS Nominating Committee solicits your nominations to elect the 2017-2018 Board of Directors and Nominating Committee. Nominees must be APS members and should demonstrate leadership qualities, have the ability to develop, communicate and sustain the Society's vision, possess strategic thinking and communications skills, and have a strong dedication to the society, its members, and the purposes APS serves. The deadline to nominate is Monday, Nov. 7. Learn more.
It is an incalculable added pleasure to any one's sum of happiness if he or she grows to know, even slightly and imperfectly, how to read and enjoy the wonder-book of nature.